Immunohistochemistry (IHC)
(Immunohistochemical analysis of paraffin-embedded H. kidney section using VWF. MBS9200676 was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.)
Mouse anti-Human VWF Monoclonal Antibody | anti-VWF antibody
VWF Antibody
FC~~1:100
WB~~1:1000
Immunohistochemistry (IHC)
(Immunohistochemical analysis of paraffin-embedded H. kidney section using VWF. MBS9200676 was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.)
Immunohistochemistry (IHC)
(Immunohistochemical analysis of paraffin-embedded H. kidney section using VWF. MBS9200676 was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.)
Flow Cytometry (FC/FACS)
(Flow cytometric analysis of K562 cells using VWF(green) compared to an isotype control of mouse IgG1(blue). AP20600c was diluted at 1:100 dilution. An Alexa Fluor 488 goat anti-mouse lgG at 1:400 dilution was used as the secondary antibody.)
Flow Cytometry (FC/FACS)
(Flow cytometric analysis of K562 cells using VWF(green) compared to an isotype control of mouse IgG1(blue). AP20600c was diluted at 1:100 dilution. An Alexa Fluor 488 goat anti-mouse lgG at 1:400 dilution was used as the secondary antibody.)
Western Blot (WB)
(Western blot analysis of lysate from VWF protein, using VWF Antibody. MBS9200676 was diluted at 1:1000. A goat anti-mouse IgG H&L(HRP) at 1:3000 dilution was used as the secondary antibody. Lysate at 35ug.)
Western Blot (WB)
(Western blot analysis of lysate from VWF protein, using VWF Antibody. MBS9200676 was diluted at 1:1000. A goat anti-mouse IgG H&L(HRP) at 1:3000 dilution was used as the secondary antibody. Lysate at 35ug.)
Mancuso D.J.,et al.J. Biol. Chem. 264:19514-19527(1989).
Scherer S.E.,et al.Nature 440:346-351(2006).
Verweij C.L.,et al.EMBO J. 5:1839-1847(1986).
Verweij C.L.,et al.EMBO J. 5:3074-3074(1986).
NCBI and Uniprot Product Information
NCBI Description
The glycoprotein encoded by this gene functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease. An unprocessed pseudogene has been found on chromosome 22. [provided by RefSeq, Jul 2008]
Uniprot Description
VWF: Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Defects in VWF are the cause of von Willebrand disease type 1 (VWD1). A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 2 (VWD2). A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet- dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 3 (VWD3). A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses.
Protein type: Secreted; Secreted, signal peptide; Motility/polarity/chemotaxis; Cell adhesion; Extracellular matrix
Chromosomal Location of Human Ortholog: 12p13.3
Cellular Component: extracellular matrix; proteinaceous extracellular matrix; endoplasmic reticulum; extracellular region; external side of plasma membrane
Molecular Function: integrin binding; collagen binding; identical protein binding; protein binding; protein homodimerization activity; protease binding; chaperone binding; immunoglobulin binding; protein N-terminus binding; glycoprotein binding
Biological Process: platelet activation; extracellular matrix organization and biogenesis; platelet degranulation; hemostasis; response to wounding; cell adhesion; liver development; blood coagulation; blood coagulation, intrinsic pathway; protein homooligomerization; cell-substrate adhesion; placenta development
Disease: Von Willebrand Disease, Type 3; Von Willebrand Disease, Type 1; Von Willebrand Disease, Type 2
Research Articles on VWF
Similar Products
Product Notes
The VWF vwf (Catalog #AAA9200676) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The VWF Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's VWF can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), ELISA (EIA), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS). IHC~~1:25 FC~~1:100 WB~~1:1000. Researchers should empirically determine the suitability of the VWF vwf for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "VWF, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
